Instylla, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Instylla, Inc. - overview
Established
2017
Location
Bedford, MA, US
Primary Industry
Medical Devices & Equipment
About
Based in the US, Instylla, Inc. operates as a medical technology company specializing in next-generation liquid embolics for interventional radiology, focusing on effective solutions for oncology and vascular treatments. Instylla, Inc. was founded in 2017 and is headquartered in Bedford, US.
The company focuses on developing innovative solutions in interventional radiology. In August 2023, Instylla raised USD 30. 03 mn in Series B funding led by Delos Capital Partners, with participation from AMED Ventures, Ascension Ventures, Catalyst Health Ventures, Excelestar Ventures, Incept, and Sparta Group. The total amount raised to date is USD 30.
03 mn, leading to a current company valuation of USD 131. 628 mn. Instylla, Inc. specializes in the development of next-generation liquid embolics for applications in interventional radiology, with core products including the Embrace Hydrogel Embolic System and the Tembo Embolic System.
These products aim to provide precise delivery of embolic agents to occlude blood vessels, addressing critical medical conditions such as tumors and bleeding. Instylla’s offerings cater primarily to hospitals and healthcare providers in North America and Europe, focusing on advanced interventional therapies. Instylla operates on a business-to-business (B2B) model, generating revenue through direct sales of its embolic systems via supply agreements and contracts with healthcare organizations. The Embrace Hydrogel Embolic System and the Tembo Embolic System are central to its revenue strategy, with bulk orders from healthcare facilities integrating these products into their interventional practices.
Specific pricing and transaction volumes are proprietary and negotiated with healthcare partners. In August 2023, Instylla, Inc. raised USD 30. 3 mn in Series B funding, led by Delos Capital Partners with contributions from several other investors.
This funding will be utilized to support the commercialization and clinical testing of its product. Plans are underway to launch new products designed for the interventional radiology market and expand into additional geographic regions, particularly in Europe and Asia, by 2024.
Current Investors
Catalyst Health Ventures, Ascension Ventures, Excelestar Ventures
Primary Industry
Medical Devices & Equipment
Sub Industries
Surgical Devices
Website
www.instylla.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.